In the last two decades, deregulated CatB synthesis and activity have been reported to be involved in the pathology of several diseases, such as cancer [9, 10, 11, 12], pancreatitis [13], liver fibrosis [14], rheumatoid arthritis [15, 16], inflammatory pain [17], traumatic brain injury [18], hypoxia‐ischemic brain injury [19], Alzheimer's disease [20, 21, 22, 23], and COVID‐19 infection [24, 25]. Here, TYRP1 is linked to early-onset autosomal dominant Alzheimer disease.